ERBB2 and breast cancer: Gene expression profiling of BC has enabled its classification into four clinically relevant BC subtypes; two ER+ subtypes (Luminal A and Luminal B) with favorable clinical outcomes as compared to the two ER− subtypes (triple negative/basal-like and human epidermal growth factor receptor 2 (HER2) enriched) [5–8].